Overview

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fudan University
Treatments:
Gemcitabine
Paclitaxel
Criteria
Inclusion Criteria:

- Ability to understand and the willingness to sign a written informed consent document.

- Age ≥ 18 years and ≤ 80 years.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

- Histologically or cytologically confirmed advanced pancreas adenocarcinoma.

- Primary pancreatic cancer without major anti-cancer treatments.

- Locally advanced, or metastatic pancreatic cancer.

- Presence of at least of one measurable lesion in agreement to RECIST criteria.

- The expected survival ≥ 3 months.

- Adequate organ performance based on laboratory blood tests.

- Patients who are willing or able to comply with study procedures.

Exclusion Criteria:

- Pregnant or nursing women.

- Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.

- The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.

- Inflammation of the digestive tract, including pancreatitis, cholecystitis,
cholangitis, etc.

- Severe and uncontrollable accompanying diseases that may affect protocol compliance or
interfere with the interpretation of results.

- Cardiovascular and cerebrovascular accidents.

- Allergic to study drugs.

- Other serious accompanying illnesses, which, in the researcher's opinion, could
seriously adversely affect the safety of the treatment.